Clinical Trials Logo

Blood Clot clinical trials

View clinical trials related to Blood Clot.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03365999 Completed - Knee Osteoarthritis Clinical Trials

Oral Tranexamic Acid vs. Oral Aminocaproic Acid to Reduce Blood Loss and Transfusion After Total Knee Replacement.

Start date: October 15, 2017
Phase: Phase 2
Study type: Interventional

This study compares two oral medications (tranexamic acid and aminocaproic acid) as hemostatic agent administered in patients undergoing total knee replacement.

NCT ID: NCT03280368 Completed - Atrial Fibrillation Clinical Trials

Adherence and Coagulation Assays in Dabigatran-treated Patients With Atrial Fibrillation

ARCADE
Start date: June 2014
Phase:
Study type: Observational

In patients with non-valvular atrial fibrillation treated with dabigatran etexilate, the level of adherence will be measured using a questionnaire, the Danish National Prescription Registry and pillcount and will be related to plasma levels of dabigatran measured by liquid chromatography tandem mass spectrometry (LC-MS/MS) and coagulation assays. The aim of the study is to measure the level of adherence and evaluate the usefulness of different coagulation assays to measure adherence in these patients. Furthermore, the aim is to determine the correlation between the anticoagulant effect of dabigatran using different coagulation assays and plasma levels of dabigatran. Most studies so far have been performed in vitro with plasma samples spiked with dabigatran. In this study the present knowledge from results of coagulation assays in dabigatran spiked plasma samples will be compared to the results of coagulation assays using blood samples from real-life patients.

NCT ID: NCT03274674 Completed - Condition Clinical Trials

Use of Injectable-platelet-rich-fibrin (I-PRF) to Thicken Gingival Phenotype

Start date: April 4, 2017
Phase: N/A
Study type: Interventional

The main objective of this study is to investigate whether the for individuals with thin gingival thickness who are susceptible to gingival recession, the investigators will use i-PRF with microneedle to increase gingival thickness without the need for surgical procedures

NCT ID: NCT02984384 Completed - Trauma Clinical Trials

PREVENTion of Clot in Orthopaedic Trauma

PREVENT CLOT
Start date: April 24, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare aspirin versus low-molecular weight heparin (LMWH) (Enoxaparin) as a thromboprophylaxis in patients who sustain a fracture.

NCT ID: NCT02744092 Completed - Cancer Clinical Trials

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

CANVAS
Start date: December 13, 2016
Phase: N/A
Study type: Interventional

The overarching objective of the study is to determine the effectiveness of LMWH/ warfarin vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients. The intervention strategy is Direct Oral AntiCoagulants (DOAC) therapy with edoxaban, apixaban, rivaroxaban, or dabigatran. The comparator is low molecular weight heparin (LMWH) alone or with warfarin. The information gained will empower cancer patients and physicians to make more informed choices about anticoagulation strategies to manage VTE.

NCT ID: NCT01743898 Completed - Blood Clot Clinical Trials

A Prospective Pharmacodynamic Study of Rivaroxaban

Start date: October 2012
Phase: N/A
Study type: Observational

The ability to explain bleeding or clotting complications in patients treated with rivaroxaban remains challenging. In addition, there is limited data on how coagulation tests perform in patients treated with therapeutic doses of rivaroxaban. Predicted responses of coagulation tests to therapeutic doses of rivaroxaban may be helpful in better understanding abnormal responses to rivaroxaban. The purpose of the study is to define a therapeutic reference range for peak and trough coagulation tests in patients taking FDA approved doses of rivaroxaban and to determine which tests may be most clinically useful for monitoring rivaroxaban.